【摘要】 目的 探究糖尿病性视网膜黄斑水肿患者使用注射雷珠单抗的治疗效果。方法 选取2023年5月—2024年5月惠安县医院收治的78例糖尿病性视网膜黄斑水肿患者，根据治疗方式差异分为对照组（39例，激光手术治疗）、观察组（39例，在对照组基础上辅以雷珠单抗治疗）。比较两组临床相关指标水平、实验室指标水平、不良反应。结果 治疗后，相较于对照组，观察组最佳矫正视力、黄斑中心凹视网膜厚度均更优，血清成纤维细胞生长因子、血管内皮生长因子、胰岛素样生长因子1均更低，差异均有统计学意义（P均<0.05）。不良反应发生率组间比较，差异无统计学意义（P>0.05）。结论 对糖尿病性视网膜黄斑水肿患者辅以雷珠单抗注射液，可取得较理想的临床效果，调节成纤维细胞生长因子、血管内皮生长因子、胰岛素样生长因子1水平，改善视功能，以及保障患者临床治疗安全性。更多还原

【Abstract】 Objective To explore the therapeutic effect of intravitreal ranibizumab injection in patients with diabetic retinopathy-macular edema. Methods A total of 78 patients with diabetic macular edema admitted to Hui’an County Hospital from May 2023 to May 2024 were selected. According to the difference in treatment methods, they were divided into a control group and an observation group, with 39 cases in each group. The control group was treated with laser surgery, while the observation group received adjuvant ranibizumab treatment on the basis of the control group’s therapy. The levels of clinical related indexes, laboratory indexes and adverse reactions were compared between the two groups. Results After treatment, compared with the control group, the observation group showed better best-corrected visual acuity and macular foveal retinal thickness; meanwhile, the serum levels of fibroblast growth factor, vascular endothelial growth factor and insulin-like growth factor-1 in the observation group were lower, and the differences were statistically significant(all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The application of ranibizumab injection in patients with diabetic macular edema can achieve ideal clinical results, regulate the levels of fibroblast growth factor, vascular endothelial growth factor and insulin-like growth factor 1, improve visual function, and ensure the safety of clinical treatment.更多还原